The Rogel Cancer Center has awarded $125,000 (direct costs) for their Rogel Cancer Center Innovation Grant – Fall 2025 submission: “SAFE-ENGAGER: Specific Activation and Functional Engagement of vaccine-primed T cells via TCR-binding bispecific T cell engager for potent and safe immunotherapy.” The project is funded for 12/01/25 – 11/30/26. The Rogel Cancer Center congratulates Dr. Zhu and Dr. Castro on this recognition and is proud to support their innovative work in cancer immunotherapy.